Vaccinia Vaccination (ACAM2000) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV)
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2018
At a glance
- Drugs ACAM 2000 (Primary) ; Vaccinia immune globulin (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Emergent BioSolutions
- 14 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Aug 2019.
- 14 Feb 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Feb 2019.
- 21 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.